헤파린 시장 규모는 2024년에 97억 6,761만 달러에 달했습니다. 이 시장은 2025년부터 2032년까지 예측 기간 동안 8.12%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 181억 8,809만 달러에 달할 것으로 예상됩니다. 세계 헤파린 시장은 의약품 시장을 형성하는 다양한 요인에 의해 주도되고 있습니다. 우선, 심혈관 질환과 암의 전 세계 유병률 증가가 헤파린 수요를 주도하고 있습니다. 이러한 질환은 생명을 위협하는 혈전을 예방하기 위해 항응고 요법을 필요로 하는 경우가 많습니다. 또한, 특히 수술, 외상, 종양 치료에서 전혈 및 혈액 성분에 대한 수혈 수요가 증가함에 따라 수혈 과정에서 혈전 형성을 방지하는 데 매우 중요한 헤파린의 필요성이 더욱 증가하고 있습니다. 또한 저분자량 헤파린(LMWH) 및 새로운 제형 개발을 포함한 세계 제품 개발 활동 증가는 헤파린의 접근성과 안전성을 향상시켜 2025년부터 2032년까지의 예측 기간 동안 전체 시장 성장을 가속할 것으로 예상됩니다.
세계심장연맹(2024년)에 따르면 전 세계적으로 약 6,000만 명이 심방세동을 앓고 있습니다. 또한, 이 자료에 따르면 심방세동 환자는 뇌졸중 발생 가능성이 5배나 높다고 합니다.
또한, 영국심장재단(British Heart Foundation)이 제공한 최근 데이터(2024년)에 따르면, 전 세계적으로 약 5,600만 명의 여성과 4,500만 명의 남성이 뇌졸중 생존자입니다. 전 세계적으로 최소 1,300만 명이 선천성 심장질환을 앓고 있는 것으로 추정되며, 잠재적으로 수백만 명이 더 진단되지 않은 것으로 추정됩니다.
또한, 영국 심장 재단이 제공한 최근 데이터(2024년)에 따르면, 관상동맥(허혈성) 심장질환은 전 세계적으로 약 2억 명이 앓고 있는 것으로 추산됩니다. 약 1억 1,000만 명의 남성과 8,000만 명의 여성이 이 질환을 앓고 있습니다. 또한, 약 5,600만 명의 여성과 4,500만 명의 남성이 뇌졸중 생존자입니다.
불안정성 관상동맥질환(CAD) 치료에서 치료용량의 미분획 헤파린은 사망 및 심근경색을 포함한 허혈의 유해한 결과를 감소시키는 데 효과적임이 입증되었습니다. 또한, 헤파린의 정맥 투여는 불안정성 관상동맥질환 발병 후 향후 심장질환을 예방하는 데 중요한 역할을 합니다. 유사한 항혈전 특성을 가진 저분자 헤파린(LMWH)은 피하 투여의 장점을 가지고 있어 심혈관계 환자의 장기적인 관리에 적합합니다. 이러한 유연성과 효과로 인해 심혈관 치료의 중요한 요소로서 헤파린에 대한 세계 수요가 증가하고 있습니다.
마찬가지로 암 환자는 혈전색전성 합병증 발생 위험이 높아 치료를 위해 항응고제를 사용해야 하는 경우가 많습니다. 예를 들어, GLOBOCAN이 제공한 최근 데이터(2024년)에 따르면, 2022년 전 세계에서 새로 발생한 암 환자 수는 2,000만 명으로 추산되며, 2045년까지 3,260만 명으로 증가할 것으로 예측됩니다. 암 치료 중 화학요법과 장기적인 고정은 암 관련 혈전증이 흔한 부작용이기 때문에 이러한 필요성을 더욱 증가시키고 있습니다. 항응고제인 헤파린은 혈전 형성에 관여하는 단백질을 억제하여 혈전 예방 및 치료에 도움을 줍니다. 이를 통해 심부정맥혈전증(DVT), 폐색전증, 뇌졸중과 같은 질환의 위험을 줄일 수 있어 전 세계적으로 헤파린에 대한 수요가 증가하고 있습니다.
또한, 헤파린 시장은 제품 개발, 연구 개발 노력, 임상시험 및 전 세계 규제 당국의 승인에 힘입어 빠르게 성장하고 있습니다. 예를 들어, 2022년 1월 Optimvia와 Ginkgo Bioworks는 현재 산업 축산에서 생산되는 필수 의약품인 생합성 헤파린의 생산 효율을 개선하기 위한 제휴를 발표했습니다. 이번 제휴를 통해 옵티엠비아는 은행나무의 세포 및 효소 공학 플랫폼과 발효 공정 개발 전문성을 활용하여 옵티엠비아의 생합성 헤파린 생산 기술의 성능을 빠르게 향상시키는 것을 목표로 하고 있습니다.
따라서, 위의 요인들은 2025년부터 2032년까지 예측 기간 동안 전 세계 헤파린 시장 전체를 견인할 것으로 예상됩니다.
세계의 헤파린(Heparin) 시장에 대해 조사했으며, 시장 개요와 함께 기원별, 투여 경로별, 용도별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 전해드립니다.
Heparin Market by Source (Bovine, Porcine, and Others), Route of Administration (Subcutaneous and Intravenous), Application (Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, Renal Impairment, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of cardiovascular disorders and cancer globally, growing demand for whole blood and blood component transfusion and blood donation, and increase in product development activities across the globe.
The heparin market was valued at USD 9,767.61 million in 2024, growing at a CAGR of 8.12% during the forecast period from 2025 to 2032 to reach USD 18,188.09 million by 2032. The global heparin market is propelled by a convergence of factors shaping the pharmaceutical landscape. Firstly, the increasing prevalence of cardiovascular disorders and cancer globally is driving the demand for heparin, as these conditions often require anticoagulation therapy to prevent life-threatening blood clots. Additionally, the growing demand for whole blood and blood component transfusions, especially in surgeries, trauma cases, and oncology treatments, further supports the need for heparin, which is crucial in preventing clot formation during transfusion procedures. Furthermore, the rise in product development activities across the globe, including advancements in low molecular weight heparin (LMWH) and novel formulations, enhances the accessibility and safety of heparin, boosting its overall market growth during the forecasted period from 2025 to 2032.
Heparin Market Dynamics:
According to the World Heart Federation (2024), approximately 60 million population globally were affected by atrial fibrillation. Additionally, as per the same source people with atrial fibrillation are 5X times more likely to suffer a stroke.
Moreover, according to the recent data provided by the British Heart Foundation (2024), globally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.
Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, affected an estimated 200 million people globally. Approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors.
In the treatment of unstable coronary artery disease (CAD), therapeutic-dose unfractionated heparin has proven effective in reducing adverse ischemic outcomes, including death and myocardial infarction. Additionally, intravenous heparin plays a crucial role in preventing future cardiac events following an episode of unstable CAD. Low-molecular-weight heparin (LMWH), which shares similar antithrombotic properties, offers the advantage of subcutaneous administration and is well-suited for long-term management of cardiovascular patients. This flexibility, combined with its efficacy, has led to a rising global demand for heparin as a vital component of cardiovascular care.
Similarly, cancer patients are often at high risk of developing thromboembolic complications, which necessitates the use of anticoagulants for treatment. For instance, as per the recent data provided by GLOBOCAN (2024), in 2022, globally, the estimated number of new cases of cancer was 20 million and the projections were estimated to increase by 32.6 million by 2045. Chemotherapy and prolonged immobilization during cancer therapy further contribute to this need, as cancer-associated thrombosis is a common side effect. Heparin, an anticoagulant, helps prevent and treat these clots by inhibiting proteins involved in clot formation. This reduces the risk of conditions such as deep vein thrombosis (DVT), pulmonary embolism, and strokes, thus driving the growing demand for heparin in the market across the globe.
Additionally, the growing demand for whole blood and blood component transfusions and donations is significantly boosting the global heparin market, as heparin is essential in preventing clot formation during these processes. This anticoagulant ensures the safe handling of blood products, maintaining fluidity during collection, processing, and transfusion. According to the recent data provided by the World Health Organization (2023), globally, 118.5 million blood donations were collected in 2023, with 40% originating from high-income countries (WHO). The rate of blood donations per 1,000 people varies significantly by income level, further illustrating global disparities in access to blood and blood products. Heparin is vital in the collection and processing of these components, ensuring proper separation of RBCs, plasma, and platelets. As healthcare systems worldwide emphasize safe transfusion practices, the use of heparin in blood management protocols is increasing, driving the demand for heparin products and contributing to the overall growth of the global heparin market.
Furthermore, the heparin market is experiencing rapid growth, fueled by significant advancements in product development, R&D efforts, clinical trials, and regulatory approvals across the globe. For instance, in January 2022, Optimvia and Ginkgo Bioworks announced a partnership to improve the manufacturing efficiency of biosynthetic heparin, an essential medicine currently produced from industrial animal agriculture. Under the partnership, Optimvia seeks to leverage Ginkgo's cell and enzyme engineering platform, as well as its fermentation process development expertise, to rapidly improve the performance of Optimvia's biosynthetic heparin manufacturing technology.
Thus, the factors mentioned above are expected to boost the overall market of heparin across the globe during the forecast period from 2025 to 2032.
However, Potential and fatal side effects associated with the use of heparin and the availability of alternative methods of anticoagulation may hinder the future market of heparin across the globe during the forecasted period.
Heparin Market Segment Analysis:
Heparin Market by Source (Bovine, Porcine, and Others), Route of Administration (Subcutaneous and Intravenous), Application (Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, Renal Impairment, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
The porcine category in the heparin market is estimated to dominate the market with a market share of 87.30% in 2024. Porcine-derived heparin is a major contributor to the growth of the heparin market due to its widespread use in medical treatments and the increasing demand for anticoagulant therapies globally. Heparin, which is primarily extracted from the intestines of pigs, plays a vital role in preventing and treating conditions like deep vein thrombosis, and pulmonary embolism, and in patients undergoing surgeries such as cardiac bypass, dialysis, and organ transplants. The global reliance on porcine-derived heparin stems from its efficacy, established safety profile, and long history of use in both hospital settings and outpatient care. As the number of surgeries and medical procedures requiring anticoagulation therapy rises, particularly with the aging population and increasing prevalence of cardiovascular diseases, the demand for heparin, including porcine-sourced versions, continues to grow.
Additionally, clinicians had substantial experience with porcine heparin, resulting in well-established dosing procedures and monitoring techniques. However, the reliance on a single animal source and country of origin emphasizes the need to diversify the heparin supply chain. Although both bovine and porcine heparin are efficient anticoagulants, their potency varies. Bovine heparin is only proven to be around two-thirds as powerful as swine heparin, which may demand dosage modifications when switching between the two sources, making porcine heparin a preferred choice in terms of potency.
Also, in October 2023, Miratorg, a Russian pork company and a Russian subsidiary of the Van Hessen Group opened the Geparinus factory in the Kursk region. The factory aimed to produce medicinal heparin in its basic form as well as hydrolyzed feed protein. Miratorg stated that Geparinus will process mucosa from both the company's slaughterhouses and other market competitors, and was designed to treat 40,000 tons of mucosa per year, producing 70 tonnes of medicinal heparin.
Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of heparin across the globe.
North America is expected to dominate the overall heparin market:
Among all regions, North America is estimated to hold the largest share of 38.59% in the global heparin market in 2024, growing at a CAGR of 7.62% during the forecast period from 2025 to 2032. This can be attributed to the increasing prevalence of chronic disorders such as cardiovascular diseases, and diabetes, among others. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of heparin across the region. Furthermore, the growing demand for whole blood and blood component transfusions and the increase in cancer cases can further propel the market across the region.
According to the recent data provided by the Centre for Disease Control and Prevention (2024), in 2022, approximately 4.9% of adults have been diagnosed with coronary heart disease.
Additionally, as per the recent data provided by the Centre for Disease Control and Prevention (2024), approximately 12.1 million population in the United States will have atrial fibrillation by 2023.
Additionally, as per the same source each year, over 795,000 individuals in the United States experience a stroke. Of these, approximately 610,000 are first-time or new strokes. Nearly 185,000 strokes, accounting for almost 1 in 4, occur in people who have already had a stroke.
Heparin is widely used as an anticoagulant to prevent and manage complications associated with CVDs, including deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome (ACS). For patients undergoing cardiac surgeries, including coronary artery bypass grafting (CABG) or percutaneous coronary interventions (PCI), heparin is often administered to prevent clot formation during and after the procedure. Heparin's ability to quickly and effectively prevent thrombosis makes it a preferred choice for such high-risk cardiovascular treatments. Additionally, as the incidence of atrial fibrillation (AF) rises a condition that increases the risk of stroke and is commonly linked to cardiovascular diseases there is an increased need for anticoagulation therapy to reduce stroke risk, further boosting the demand for heparin.
Moreover, the increasing use of heparin highlights the rapid adoption and increases product approval across the region, which is expected to drive market growth. For instance, in November 2023, the FDA approved a taurolidine plus heparin (DefenCath(R)) catheter lock solution to reduce catheter-related bloodstream infections in patients receiving maintenance hemodialysis via a central venous catheter (CVC).
Thus, the above-mentioned factors are expected to escalate the market of heparin in the region.
Heparin Market Key Players:
Some of the key market players operating in the heparin market include Pfizer Inc., Dr. Reddy's Laboratories Ltd., Gland Pharma Limited, Sanofi, B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Novartis AG, Baxter, Leo Pharma A/S, Cardinal Health, and others.
Recent Developmental Activities in the Heparin Market:
Key Takeaways From the Heparin Market Report Study
Target Audience Who Can be Benefited From This Heparin Market Report Study
Frequently Asked Questions for the Heparin Market: